Rewriting Genetic Fate: Katherine High and the Rise of Gene Therapy
LUND SPRING SYMPOSIUM – When Katherine A. High began working with gene therapy, the field was new, promising – and riddled with uncertainty. Three decades later, she is a visiting professor at The Rockefeller University, CEO of RhyGaze AG, and former President and Head of R&D at Spark Therapeutics. Her research has led to life-changing treatments for patients with inherited diseases. But the road
https://www.medicine.lu.se/article/rewriting-genetic-fate-katherine-high-and-rise-gene-therapy - 2025-10-07